Participated · Series D · Mar 2022

OpenSpace provides jobsite capture and AI-powered analytics that stitch 360° camera and LiDAR scans to create a digital twin pinned to floor plans, typically making capture available in about 15 minutes. The system integrates into standard construction workflows, enabling remote coordination, reducing travel and miscommunications, and providing a historical record of projects. The company has expanded capture capabilities beyond 360° imagery to include 3D scans from LiDAR‑enabled iPhones and iPads and introduced ClearSight Progress Tracking to classify and quantify materials and percent complete. Since founding in 2017, customers have used OpenSpace on more than 14,000 jobsites and the platform has captured over 10 billion square feet of jobsite imagery. Led by CEO and co-founder Jeevan Kalanithi, OpenSpace plans to use new funds to continue scaling the business and develop additional AI-powered technologies. The company also recently added Alan Henricks as an independent board director alongside its existing board members. OpenSpace is described as a global leader in 360-degree jobsite capture and AI-powered analytics for construction. Its core product lets builders attach an off-the-shelf 360° camera to a hardhat, upload video to the cloud, and uses computer vision to stitch images and pin them to floor plans, creating a single source of truth. The company has expanded its offerings to include ClearSight Progress Tracking, the freemium OpenSpace Basic, and 3D Scan for LiDAR-enabled iPhones and iPads. OpenSpace reports usage on over 10,000 jobsites, with more than 500 started in the last month and over 7 billion square feet of imagery captured. Revenues have doubled or tripled each year since its 2017 founding. The company says it will continue scaling the business, widen its international footprint, and develop additional AI-powered technologies to meet growing demand. OpenSpace provides a 360° construction photo documentation and analysis platform that combines simple 360° cameras, computer vision and AI to capture complete visual records of jobsites. The platform stores imagery in the cloud to share progress and track work across projects. Customers have used the platform to capture more than four billion square feet of imagery from active construction projects across thousands of sites in over fifty countries. The company was founded in 2017 by CEO Jeevan Kalanithi and is headquartered in San Francisco, California. OpenSpace plans to expand its ClearSight analytics suite into areas such as safety management and quality control and to accelerate international expansion. Financially, the company recently raised $55M in a Series C to support these initiatives. OpenSpace provides a solution combining 360° cameras, computer vision, and AI to capture, organize, and analyze complete visual records of construction jobsites. Builders attach a small 360° camera to their hardhat, mark a starting point in the OpenSpace app, walk the site, and the software automatically captures, uploads, pins imagery to floorplans, and stitches images without manual input. Users can virtually walk through sites, track changes over time, add notes and change requests, and compare site photos side-by-side with BIM using the ClearSight analytics platform. Founded in 2017 and led by CEO Jeevan Kalanithi, the company has projects in 30 countries and customers have used the platform to capture over a billion square feet across thousands of active construction sites. Customers include Capital One, JLL, Lee Kennedy, Suffolk, and Tishman Speyer. The company raised $15.9M in Series B funding to meet demand for its remote construction technology and ClearSight analytics platform. OpenSpace is an AI-powered construction tech company that automatically creates navigable 360° photo representations of job sites. Builders attach an off-the-shelf 360° camera to their hardhat and walk the site; OpenSpace handles image capture, uploads the data to the cloud, maps images against site plans, organizes them and stitches them into a navigable photo representation that can be compared over time. The company leverages algorithms and computer vision to map and organize imagery against site plans and build a dataset of site visuals. OpenSpace plans to use new funding to scale operations, expand sales and marketing, and develop additional computer-vision-powered products that leverage its dataset. Founded in 2017 by Jeevan Kalanithi and based in San Francisco, the platform is deployed on projects exceeding $50B in total value in the United States and around the world. The company recently raised $14M in a Series A to support these initiatives.

Participated · Equity · Sep 2020

Green Monday Holdings manufactures plant-based pork substitutes and prepared frozen meals under its OmniFoods brand and operates vegetarian-focused retail outlets and cafes under Green Common. The company grew out of a Hong Kong social movement started on Earth Day in 2012 and is the business arm of the Green Monday advocacy organization founded by David Yeung and Francis Ngai. Green Monday said it raised $70 million in financing to fund expansion and other initiatives. Planned uses include entering 10 new markets across Asia, Africa, Europe, the Middle East and North America, adding 20,000 retail outlets for its products, and opening flagship Green Common stores in China and Singapore. The investment also brought a strategic partnership with conglomerate Swire Pacific, which already serves OmniPork onboard Cathay Pacific and is exploring retail and supply-chain collaborations. Investors named in the round include TPG’s The Rise Fund, Swire Pacific, CPT Capital, Jefferies Group and Sino Group’s Ng Family Trust, alongside previous corporate and celebrity backers.

Participated · Series F · May 2013

Proteus Digital Health develops digital medicines combining an ingestible sensor, a wearable patch, mobile apps and data analytics to provide objective summaries of drug ingestion and physiologic data. Its flagship product, ABILIFY MYCITE, is an FDA‑approved drug‑device combination that pairs aripiprazole tablets embedded with an ingestible event marker, the MYCITE Patch, and a companion app and dashboards. The company holds more than 450 issued patents and has regulatory clearances in the U.S., European Union and China. Proteus plans to expand its portfolio by integrating its sensors with other therapies, develop next‑generation product features and sensor capabilities, and pursue broader commercialization and software integration. The expanded collaboration with Otsuka dedicates joint teams for commercial development, software integration and standardization, manufacturing and supply‑chain coordination. Proteus is privately held by investors that include Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka and ON Semiconductor. Proteus Discover combines an FDA-cleared ingestible sensor co-encapsulated with medications, a small wearable patch, patient and provider applications, and data analytics to record dosing times and physiologic metrics such as heart rate and activity. The ingestible sensor is described as the size of a grain of sand and, when taken, signals the patch which logs medication-taking and physiologic responses. The company currently markets a co-encapsulation model and is pursuing further FDA review for a panel of Digital Medicines with the sensor directly integrated into medications. Proteus plans to drive increased adoption of Proteus Discover by partnering with health system customers to demonstrate outcomes achievable with Digital Medicines. The company says the new capital will strengthen its balance sheet and provide funding to expand its Digital Medicine platform and commercial efforts. Proteus Digital Health develops digital medicines that integrate pharmaceuticals with ingestible sensors, wearable devices, mobile and cloud computing to provide the digital health feedback system. Its core products include ingestible sensors and wearable devices; Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for those devices. The company says its platform provides an unprecedented view into patients’ health choices and physiologic responses and enables new information-based business models. Proteus is privately held and headquartered in Redwood City, Calif., and is funded by institutional and strategic investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle and ON Semiconductor. The company completed a financing process in which it announced a $120 million first part on June 2 and then completed a second closing of its Series G financing raising over $172 million. Proteus intends to use the funding to advance manufacturing and commercialization of its digital medicines. Proteus Digital Health develops digital medicine products that combine tiny ingestible sensors, wearable sensor devices, and a digital health feedback system. The company's core product embeds a tiny sensor in pharmaceuticals that communicates medication-taking behavior and how a patient’s body is responding. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable sensor devices. Led by CEO Andrew Thompson, the company is working to define an innovative category of products, services and data systems called Digital Medicines. Financially, Proteus secured a $31.6M debt financing package whose proceeds will be used for working capital growth. The company is funded by investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and others. Proteus Digital Health develops Digital Medicines built around ingestible sensors and a digital health feedback system that communicates medication-taking behavior and physiologic response. Its core product set includes ingestible sensors and wearable devices plus data systems intended to enable new care paradigms and information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and ingestible sensor devices. The company says it aims to embed its technology into established products and services to accelerate its mission and change healthcare. Proteus completed a second closing of its Series F financing, raising $62.5 million in total. It is privately held and funded by investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and others; the recent financing added corporate investor Oracle alongside Otsuka, Novartis and Sino Portfolio.